Cyanosis secondary prevention

Cyanosis Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cyanosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cyanosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cyanosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cyanosis secondary prevention
CDC on Cyanosis secondary prevention
Cyanosis secondary prevention in the news
Blogs on Cyanosis secondary prevention
Directions to Hospitals Treating Cyanosis
Risk calculators and risk factors for Cyanosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Secondary Prevention

All infants with severe PPHN who have been treated with inhaled nitric oxide (iNO) and/or extracorporeal membrane oxygenation (ECMO) should have neurodevelopmental follow-up [15]. Assessment should be performed through infancy at 6- to 12-month intervals, and longer if abnormalities are present. Hearing should be tested prior to hospital discharge and at 18 to 24 months corrected age.